BeyondSpring Past Earnings Performance

Past criteria checks 0/6

BeyondSpring has been growing earnings at an average annual rate of 15.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 47.6% per year.

Key information

15.4%

Earnings growth rate

25.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate47.6%
Return on equityn/a
Net Margin-829.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

Jun 21
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring, Beyond Salvage

Feb 03

Circling Back On BeyondSpring

Nov 16

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

Sep 18

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22
How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

Revenue & Expenses Breakdown

How BeyondSpring makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:BYSI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242-16910
31 Mar 242-181012
31 Dec 232-211015
30 Sep 232-241018
30 Jun 232-281121
31 Mar 231-301223
31 Dec 221-331326
30 Sep 221-351526
30 Jun 221-462328
31 Mar 221-562833
31 Dec 211-643137
30 Sep 211-723640
30 Jun 211-683340
31 Mar 211-622639
31 Dec 200-612342
30 Sep 200-571546
30 Jun 200-521145
31 Mar 200-471039
31 Dec 190-38931
30 Sep 190-38931
30 Jun 190-44838
31 Mar 190-49744
31 Dec 180-55652
30 Sep 180-56554
30 Jun 180-57755
31 Mar 180-58956
31 Dec 170-92989
30 Sep 170-80877
30 Jun 170-67565
31 Mar 170-58356
31 Dec 160-12210
30 Sep 160-1029
30 Jun 160-928
31 Mar 160-816
31 Dec 150-816

Quality Earnings: BYSI is currently unprofitable.

Growing Profit Margin: BYSI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BYSI is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.

Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).


Return on Equity

High ROE: BYSI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 07:38
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeyondSpring Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Jason Matthew GerberryBofA Global Research
Joshua SchimmerEvercore ISI